Similarly, in experimental autoimmune encephalomyelitis, combination therapy with lovastatin and an AMPK activator improved mitochondrial and peroxisomal function, upregulated MnSOD, and reduced disease severity, positioning MnSOD as a therapeutic effector in metabolically guided treatment of MS [227]. This evidence concerns the gene SOD2 and myeloid sarcoma.